Robert Doebele discusses TAK-788, a first-in-class inhibitor of both EGFR and HER2 shown in an early-phase study to be active in NSCLC.
Robert Doebele, MD
Advertisement
Articles by Robert Doebele, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
Sequencing CAR T-Cell Therapy With Bispecifics in Follicular Lymphoma
3
Optimal Sequencing of Bispecific Antibodies and CAR T Cells Remains Unclear
4
Ivonescimab/Chemotherapy Maintains OS Benefit in EGFR-Mutant NSCLC
5